SCHEMBL5246316

SCHEMBL5246316

O=[N+]([O-])c1ccc(Oc2c(Cl)cc(S(=O)(=O)Nc3cccc4nsnc34)cc2Cl)c(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.49
KMT2A Q03164 7/20 0.49
MAPT P10636 3/20 0.49
KDM4E B2RXH2 1/20 0.49
PKM P14618 1/20 0.49
CRHBP P24387 1/20 0.45
CRHR2 Q13324 1/20 0.45
CYP2C9 P11712 1/20 0.45
THRA P10827 3/20 0.44
POLB P06746 1/20 0.44
CASP6 P55212 1/20 0.44
CTDSP1 Q9GZU7 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CCKBR P32239 2/20 0.44
ALDH1A1 P00352 2/20 0.43
HSD17B10 Q99714 2/20 0.43
TP53 P04637 1/20 0.43
GAA P10253 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6391201 0.85 MEN1 (0.45) MEN1KMT2AMAPTKDM4EPKM
SCHEMBL1474274 0.83 CRHBP (0.52) MEN1KMT2AMAPTKDM4EPKM
SCHEMBL1472031 0.83 NFKBIA (0.64) MEN1KMT2AMAPTTHRATDP1
SCHEMBL1471692 0.82 CRHBP (0.60) MEN1KMT2AMAPTPKMCRHBP
SCHEMBL1472089 0.81 CYP2C9 (0.52) MEN1KMT2AMAPTPKMCRHBP
SCHEMBL5284276 0.81 CYP2C9 (0.42) MEN1KMT2AMAPTCRHBPCRHR2
SCHEMBL1471254 0.80 CRHBP (0.49) MEN1KMT2AMAPTKDM4EPKM
SCHEMBL1472451 0.80 THRA (0.54) MEN1KMT2AMAPTCRHBPCRHR2
SCHEMBL6764058 0.80 MEN1 (0.71) MEN1KMT2AMAPTKDM4EPKM
SCHEMBL1472302 0.80 CRHBP (0.54) MEN1KMT2AMAPTPKMCRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US claimed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP MEN1 3562/4885KMT2A 1303/4885MAPT 1681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.